In studies ranging from six to 24 months sponsored by Pfizer, the rate of cardiovascular events did not increase over time in patients treated with tofacitinib (Xeljanz) for rheumatoid arthritis (RA), despite an increase in low-density lipoprotein (LDL) cholesterol. The study suggests that the drug has little effect on cardiovascular events out to five years of treatment.

Click here for more.